Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer

Davey, Matthew G; Hynes, Seán O.; Kerin, Michael J.; Miller, Nicola; Lowery, Aoife

doi:10.3390/cancers13174455

Cited by 118 publications

(92 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results revealed that IFM-GA+laser group exhibited good anti-tumor efficacy. Then, we conducted the ki67 assessment, a test principally used for estimation of cancer prognosis [39] . The results in Fig.…”

Section: Resultsmentioning

confidence: 99%

Metal ions-bridged J-aggregation mediated nanoassembly composition for breast cancer phototherapy

Chen

Yang

Liu

et al. 2022

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Metal ions-bridged J-aggregation mediated nanoassembly composition for breast cancer phototherapy

Chen

Yang

Liu

et al. 2022

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Second, the smaller sample size compared to the wider sample size in other studies is a great contributing aspect to the complementary results in our study. Moreover, even though the predictability and prognostication of Ki67 as a biomarker is widely acknowledged, we were unable to investigate them in our study as disease free survival rates were unobtainable due to most patients being lost to follow up [ 20 ]. Finally, the relatively incomplete medical history concerning some patients was another limitation of our study.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon

Atoui

Zerdan

Mahmoud

et al. 2022

International Journal of Breast Cancer

View full text Add to dashboard Cite

Introduction. Breast cancer is considered nowadays the most prevalent cancer worldwide. The molecular era has successfully divided breast cancer into subtypes based on the various hormonal receptors. These molecular subtypes play a major role in determining the neoadjuvant chemotherapy to be administered. It was noted that the use of neoadjuvant chemotherapy was associated with higher achievement of pathological complete response. The aim of the study was to determine the predictive role of breast cancer subtypes in the efficacy and prognosis of neoadjuvant chemotherapy regimens. Methods. Combining dose dense anthracycline-based, regular dose anthracycline-based, and nonanthracycline-based chemotherapy, we observed data from 87 patients with breast cancer who received surgery after administration of neoadjuvant chemotherapy at our institution between January 2015 and July 2018. The patients were classified into luminal A, luminal B, HER2 overexpression, and triple negative breast cancer as well as low Ki67 (≤14%) and high Ki67 (>14%) expression groups using immunohistochemistry. Pathologic complete response was the only neoadjuvant chemotherapy outcome parameter. To evaluate variables associated with pathologic complete response, we used univariate analyses followed by multivariate logistic regression. Results. 87 patients with breast cancer were classified into different subtypes according to the 12th St. Gallen International Breast Cancer Conference. The response rate to neoadjuvant chemotherapy was significantly different ( p = 0.046 ) between the subgroups. There were significant correlations between pathological complete response (pCR) and ER status ( p < 0.0001 ), HER2 ( p = 0.013 ), molecular subtypes ( p = 0.018 ), T stage ( p = 0.024 ), N stage before chemotherapy ( p = 0.04 ), and type of chemotherapy ( p = 0.029 ). Luminal B type patients had the lowest pCR, followed by luminal A type patients. Conclusion. Evaluating molecular subtype’s significance in breast cancer prognosis warrants additional studies in our region with extensive data about patient-specific neoadjuvant chemotherapy regimens. Our study was able to reproduce results complementary to those present in the literature in other outcomes.

show abstract

“…The histopathological differences between GSM and classical GBM cannot be overlooked. GSM is rich in sarcoma components, which were insensitive to RT and chemotherapy [30], which is related to minimal statistical effectiveness.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study

Zhou

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: Gliosarcoma is a histopathological variant of glioblastoma, which is characterized by a biphasic growth pattern consisting of glial and sarcoma components. Owing to its scarcity, data regarding the impact of available treatments on the clinical outcomes of gliosarcoma are inadequate. The purpose of this retrospective cohort study was to analyze the prognostic factors of gliosarcoma. Methods By screening the clinical database of neurosurgical cases at a single center, patients with gliosarcoma diagnosed histologically from 2015 to 2021 were identified. Clinical, pathological and molecular data were gathered founded on medical records and follow-up interviews. Prognostic factors were derived using Cox proportional hazards model with backward stepwise regression analysis. Results Forty-five GSM patients were included. Median overall survival was 20.6 months (95%CI 5.8 – 35.3), and median relapse free survival was 15.2 months (95%CI 6.1 – 24.3). In multivariable analysis, total resection (p = 0.029, HR = 0.198, 95%CI 0.046 – 0.849) indicated an improved prognosis. And low expression of Ki-67 (p = 0.067, HR = 2.813, 95%CI 0.930 – 8.506) would be likely to show statistical significance. However, there might be no statistically significant survival benefit from radiotherapy (n = 33, 75%, log-rank p = 0.92), adjuvant temozolomide (n = 33, 73.3%, log-rank p = 0.78) or concurrent temozolomide (n = 36, 80%, log-rank p = 0.79). Conclusion This retrospective study with a limited cohort size has demonstrated the treatment of gross total resection and low expression of Ki-67 are beneficial for patients with GSM, while radiotherapy or temozolomide is not.

show abstract

Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer

Cited by 118 publications

References 153 publications

Metal ions-bridged J-aggregation mediated nanoassembly composition for breast cancer phototherapy

Metal ions-bridged J-aggregation mediated nanoassembly composition for breast cancer phototherapy

Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon

Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study

Contact Info

Product

Resources

About